2016


To access this material please log in or register

Register Authorize
2016/№1

Cardiac amyloidosis in clinical practice

Ukholkina G. B., Kuchin G. A., Bychkova O. P., Chikhirev O. A.
Medical Center of the Central Bank of the Russian Federation, Sevastopolsky Prospekt 66, Moscow 117593

Keywords: amyloidosis, diagnostics

DOI: 10.18087/rhfj.2016.1.2201

Amyloidosis is a group of diseases induced by deposition of fibrillary proteins. Some types of amyloidosis are associated with damage to the heart, amyloid cardiopathy, which has certain characteristic features. The heart damage is frequently observed in light chain (AL) amyloidosis, senile systemic amyloidosis (SSA) and can occur also in secondary (AA) amyloidosis. The review describes classification, diagnostics and different approaches in treatment of major amyloidosis types. The authors provide clinical examples with data from instrumental studies, laboratory tests, and autopsy to illustrate the complexity of diagnostics and characteristic features of different amyloidosis types.
  1. Douglas P. Zipes. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2004, Part V, Chapter 48.
  2. Кириченко А. А., Кроткова И. Ф. Изолированный амилоидоз сердца. Consilium Medicum. 2012;14 (10):128–130 [Kirichenko A. A., Krotkova I. F. Izolirovanny`j amiloidoz serdcza. Consilium Medicum. 2012;14 (10):128–130].
  3. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011 May 10;29 (14):1924–33.
  4. Dubrey SW, Comenzo RL. Amyloid diseases of the heart: current and future therapies. QJM. 2012 Jul;105 (7):617–31.
  5. Жданова Е. А., Гудкова К. В., Рамеев В. В., Сафарова А. Ф., Моисеев С. В. Современные представления об амилоидозе сердца. Кардиология. 2013;43 (12):70–8 [Zhdanova E. A., Gudkova K. V., Rameev V. V., Safarova A. F., Moiseev S. V. Sovremenny`e predstavleniya ob amiloidoze serdcza. Kardiologiya. 2013;43 (12):70–8].
  6. Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015 Jan;168 (2):207–18.
  7. Rosenzweig M and Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol. 2011;4:47.
  8. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015 Jan 21;36 (4):244–51.
  9. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014 Feb;99 (2):209–21.
  10. Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015 Jan;168 (2):186–206.
  11. Козловская Л. В., Рамеев В. В. Современные подходы к лечению амилоидоза. Современная медицинская наука. 2012;1:4–16 [Kozlovskaya L. V., Rameev V. V. Sovremenny`e podxody` k lecheniyu amiloidoza. Sovremennaya mediczinskaya nauka. 2012;1:4–16].
  12. Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000 Aug;93 (8):535–42.
Ukholkina G. B., Kuchin G. A., Bychkova O. P., Chikhirev O. A. Cardiac amyloidosis in clinical practice. Russian Heart Failure Journal. 2016;17 (1):57–68

To access this material please log in or register

Register Authorize
Ru En